The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer

Masatoshi Nomura, Hidekazu Takahashi, Naotsugu Haraguchi, Junichi Nishimura, Taishi Hata, Chu Matsuda, Masakazu Ikenaga, Hirofumi Yamamoto, Kohei Murata, Yuichiro Doki, Masaki Mori, Tsunekazu Mizushima

Research output: Contribution to journalArticle

Abstract

Background and purpose: Pre-operative chemotherapy is an option for patients with local advanced rectal cancer, but the response rate to pre-operative chemotherapy with oxaliplatin is still low. If the therapeutic effect of pre-operative chemotherapy could be assessed, we may be able to convert to surgery early. The purpose of the present study was to validate the correlation between the maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET–CT) of the primary tumor and the therapeutic effect of pre-operative chemotherapy in advanced colorectal cancer. Patients and methods: Retrospective cohort study from January 2011 to October 2015. We examined 28 patients with pathologically confirmed sigmoid or rectal cancer that underwent pre-operative chemotherapy and surgery. The correlation between Response Index (RI), calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy), and the therapeutic effect on the primary tumor in advanced colorectal cancer. Results: The degree of differentiation (p = 0.04), SUVmax in the primary tumor after chemotherapy (p = 0.02), and RI (p = 0.008) were significant predictors of the therapeutic effect in univariate analysis. The areas under the ROC curve constructed with RI and therapeutic effect was 0.77. The optimal cut-off values for the RI in the responder group was < 0.32. Conclusion: RI calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy) in the primary tumor significantly correlated with the therapeutic effect of chemotherapy on advanced colorectal cancer. Thus, RI is potentially useful for predicting the therapeutic effect in advanced colorectal cancer.

Original languageEnglish
Pages (from-to)1219-1226
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume80
Issue number6
DOIs
Publication statusPublished - Dec 1 2017
Externally publishedYes

Fingerprint

Positron emission tomography
Chemotherapy
Therapeutic Uses
Positron-Emission Tomography
Colorectal Neoplasms
Drug Therapy
Tumors
oxaliplatin
Rectal Neoplasms
Surgery
Neoplasms
Sigmoid Neoplasms
Fluorodeoxyglucose F18
ROC Curve
Area Under Curve
Cohort Studies
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer. / Nomura, Masatoshi; Takahashi, Hidekazu; Haraguchi, Naotsugu; Nishimura, Junichi; Hata, Taishi; Matsuda, Chu; Ikenaga, Masakazu; Yamamoto, Hirofumi; Murata, Kohei; Doki, Yuichiro; Mori, Masaki; Mizushima, Tsunekazu.

In: Cancer Chemotherapy and Pharmacology, Vol. 80, No. 6, 01.12.2017, p. 1219-1226.

Research output: Contribution to journalArticle

Nomura, M, Takahashi, H, Haraguchi, N, Nishimura, J, Hata, T, Matsuda, C, Ikenaga, M, Yamamoto, H, Murata, K, Doki, Y, Mori, M & Mizushima, T 2017, 'The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer', Cancer Chemotherapy and Pharmacology, vol. 80, no. 6, pp. 1219-1226. https://doi.org/10.1007/s00280-017-3442-2
Nomura, Masatoshi ; Takahashi, Hidekazu ; Haraguchi, Naotsugu ; Nishimura, Junichi ; Hata, Taishi ; Matsuda, Chu ; Ikenaga, Masakazu ; Yamamoto, Hirofumi ; Murata, Kohei ; Doki, Yuichiro ; Mori, Masaki ; Mizushima, Tsunekazu. / The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer. In: Cancer Chemotherapy and Pharmacology. 2017 ; Vol. 80, No. 6. pp. 1219-1226.
@article{ea0e9222a71c4b41974ff2212c9430e7,
title = "The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer",
abstract = "Background and purpose: Pre-operative chemotherapy is an option for patients with local advanced rectal cancer, but the response rate to pre-operative chemotherapy with oxaliplatin is still low. If the therapeutic effect of pre-operative chemotherapy could be assessed, we may be able to convert to surgery early. The purpose of the present study was to validate the correlation between the maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET–CT) of the primary tumor and the therapeutic effect of pre-operative chemotherapy in advanced colorectal cancer. Patients and methods: Retrospective cohort study from January 2011 to October 2015. We examined 28 patients with pathologically confirmed sigmoid or rectal cancer that underwent pre-operative chemotherapy and surgery. The correlation between Response Index (RI), calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy), and the therapeutic effect on the primary tumor in advanced colorectal cancer. Results: The degree of differentiation (p = 0.04), SUVmax in the primary tumor after chemotherapy (p = 0.02), and RI (p = 0.008) were significant predictors of the therapeutic effect in univariate analysis. The areas under the ROC curve constructed with RI and therapeutic effect was 0.77. The optimal cut-off values for the RI in the responder group was < 0.32. Conclusion: RI calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy) in the primary tumor significantly correlated with the therapeutic effect of chemotherapy on advanced colorectal cancer. Thus, RI is potentially useful for predicting the therapeutic effect in advanced colorectal cancer.",
author = "Masatoshi Nomura and Hidekazu Takahashi and Naotsugu Haraguchi and Junichi Nishimura and Taishi Hata and Chu Matsuda and Masakazu Ikenaga and Hirofumi Yamamoto and Kohei Murata and Yuichiro Doki and Masaki Mori and Tsunekazu Mizushima",
year = "2017",
month = "12",
day = "1",
doi = "10.1007/s00280-017-3442-2",
language = "English",
volume = "80",
pages = "1219--1226",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - The potential usefulness of the Response Index in positron emission tomography assessing the therapeutic effect of pre-operative chemotherapy for advanced colorectal cancer

AU - Nomura, Masatoshi

AU - Takahashi, Hidekazu

AU - Haraguchi, Naotsugu

AU - Nishimura, Junichi

AU - Hata, Taishi

AU - Matsuda, Chu

AU - Ikenaga, Masakazu

AU - Yamamoto, Hirofumi

AU - Murata, Kohei

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Mizushima, Tsunekazu

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Background and purpose: Pre-operative chemotherapy is an option for patients with local advanced rectal cancer, but the response rate to pre-operative chemotherapy with oxaliplatin is still low. If the therapeutic effect of pre-operative chemotherapy could be assessed, we may be able to convert to surgery early. The purpose of the present study was to validate the correlation between the maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET–CT) of the primary tumor and the therapeutic effect of pre-operative chemotherapy in advanced colorectal cancer. Patients and methods: Retrospective cohort study from January 2011 to October 2015. We examined 28 patients with pathologically confirmed sigmoid or rectal cancer that underwent pre-operative chemotherapy and surgery. The correlation between Response Index (RI), calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy), and the therapeutic effect on the primary tumor in advanced colorectal cancer. Results: The degree of differentiation (p = 0.04), SUVmax in the primary tumor after chemotherapy (p = 0.02), and RI (p = 0.008) were significant predictors of the therapeutic effect in univariate analysis. The areas under the ROC curve constructed with RI and therapeutic effect was 0.77. The optimal cut-off values for the RI in the responder group was < 0.32. Conclusion: RI calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy) in the primary tumor significantly correlated with the therapeutic effect of chemotherapy on advanced colorectal cancer. Thus, RI is potentially useful for predicting the therapeutic effect in advanced colorectal cancer.

AB - Background and purpose: Pre-operative chemotherapy is an option for patients with local advanced rectal cancer, but the response rate to pre-operative chemotherapy with oxaliplatin is still low. If the therapeutic effect of pre-operative chemotherapy could be assessed, we may be able to convert to surgery early. The purpose of the present study was to validate the correlation between the maximum standardized uptake value (SUVmax) in 18F-fluorodeoxyglucose positron emission tomography–computed tomography (PET–CT) of the primary tumor and the therapeutic effect of pre-operative chemotherapy in advanced colorectal cancer. Patients and methods: Retrospective cohort study from January 2011 to October 2015. We examined 28 patients with pathologically confirmed sigmoid or rectal cancer that underwent pre-operative chemotherapy and surgery. The correlation between Response Index (RI), calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy), and the therapeutic effect on the primary tumor in advanced colorectal cancer. Results: The degree of differentiation (p = 0.04), SUVmax in the primary tumor after chemotherapy (p = 0.02), and RI (p = 0.008) were significant predictors of the therapeutic effect in univariate analysis. The areas under the ROC curve constructed with RI and therapeutic effect was 0.77. The optimal cut-off values for the RI in the responder group was < 0.32. Conclusion: RI calculated as (SUVmax after chemotherapy)/(SUVmax before chemotherapy) in the primary tumor significantly correlated with the therapeutic effect of chemotherapy on advanced colorectal cancer. Thus, RI is potentially useful for predicting the therapeutic effect in advanced colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=85032380188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032380188&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3442-2

DO - 10.1007/s00280-017-3442-2

M3 - Article

C2 - 29075856

AN - SCOPUS:85032380188

VL - 80

SP - 1219

EP - 1226

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 6

ER -